Abstract A number of gene delivery systems are currently being developed for potential use in gene therapy. Here, we demonstrate the feasibility of 21DqHAC, a newly developed human artificial chromosome (HAC), as a gene delivery system. We first introduced a 21DqHAC carrying an EGFP reporter gene and a geneticin-resistant gene (EGFP-21DqHAC) into hematopoietic cells by microcell-mediated chromosome transfer. These HAC-containing hematopoietic cells showed resistance to geneticin, expressed EGFP and retained the ability to differentiate into various lineages, and the EGFP-21DqHAC was successfully transduced into primary hematopoietic cells. Hematopoietic cells harboring the EGFP-21DqHAC could still be detected at two weeks post-transplantation in immunodeficient mice. We also showed effective expansion of hematopoietic cells by introducing the 21DqHAC containing ScFvg, a gp130-based chimeric receptor that transmits growth signals in response to specific-antigen of this receptor. All of these results demonstrate the usefulness of HAC in gene therapy.
Introduction
Gene therapy holds tremendous potential for treating diseases. However, each vector system developed for gene therapy so far has advantages and disadvantages, and no ''almighty vector system'' has been established to address all needs. Here, we describe our novel approach to using chromosomes as vectors for gene delivery. The human artificial chromosome (HAC) system is a realistic choice for clinical gene therapy, because HACs have significant advantages for gene therapy, including a large capacity for DNA inserts, stable extrachromosomal maintenance in host cells and satisfactory gene expression levels (Grimes et al. 2002; Larin et al. 2002; Saffery et al. 2002) . We recently developed a novel, centromere-based HAC vector from human chromosome 21, which referred to as the 21DqHAC vector. Features of the vector include a single loxP site for sitespecific insertion of DNA via the Cre/loxP system (Kakeda et al. 2005; Katoh et al. 2004) . Our group confirmed the stability of HAC with mice bearing HAC possessing the entire human immunoglobin region (Kawahara et al. 2004) .
In this study, we evaluate the feasibility of HAC vectors for gene therapy using primary human bone marrow mononuclear cells (hBM MNC) or cord bloodderived hematopoietic cells.
Materials and methods

21DqHAC vector
The construction of the 21DqHAC vector was described in our previous report (Katoh et al 2004) . Briefly, the 21DqHAC vector was generated from human chromosome 21 in DT40 cells by removing the distal arm of chromosome 21q via telomere-directed chromosome truncation. Moreover, we introduced a loxP site between the centromere and the end of 21q, creating a site at which an additional sequence, including genes, can be introduced via the Cre-loxP system. Then the 21DqHAC vector was transferred from DT40-hybrids to CHO cells by MMCT. The EGFP-21DqHAC vector or ScFvg-21DqHAC is the 21DqHAC vector harboring an hCMV-EGFP gene or a PGK-ScFvg gene (Kawahara et al. 2004 ) respectively. The ScFvg gene is a chimeric receptor consisting of an anti-fluorescein single-chain, Fv, fused to the extracellular D2 domain of the erythropoietin receptor and the transmembrane/intracellular domains of gp130 (Kawahara et al. 2004 ). These genes were inserted at the loxP site of the 21DqHAC vector by Cre-mediated recombination.
Cell culture and microcell-mediated chromosome transfer
Human cord blood cells were obtained from volunteers who had granted their informed consent. Human cell experiments were performed according to the guidelines and with the permission of Kirin Brewery's ethical committee. Both EGFP-21DqHAC vectors and ScFvg-21DqHAC vectors retained in CHO cells were transferred to 1·10 7 hBM MNCs (AllCells, LLC, Berkeley, CA, USA) or 1·10 6 hCB CD34 + cells by microcell-mediated chromosome transfer (MMCT) as previously described (Doherty et al. 2003; Kakeda et al. 2005; Katoh et al. 2004 ). The cells were cultured for five days in the presence of 100 ng/ml hSCF, 30 ng/ml hTPO, and 20 ng/ml FP6 (Kimura et al. 2000; Ueda et al. 2000) or 1 lg/ml BSA-Fl (Sigma, St. Louis, MO, USA). Then the cells were subjected to a clonogenic assay for 12 days in the presence of 50 ng/ ml SCF, 30 ng/ml TPO, 50 ng/ml IL-6, 50 ng/ml IL-3, 50 ng/ml GM-CSF, 5IU/ml EPO (Kirin Brewery Co. Ltd., Gunma, Japan), and 800 lg/ml geneticin (Invitrogen, Inchinnan, UK).
PCR analysis of genomic DNA For colony-forming cells, the cells picked from methylcellulose culture were subjected to DNA isolation. For FACS-sorted cells, the cells were directly subjected to DNA isolation. The following oligonucleotide primers were used to detect the 21DqHAC vector: 5¢-CGTAAC-AACTCCGCCCCATT-3¢ and 5¢-CGGACAGGTCG-GTCTTGACA-3¢. This primer pair specifically detects the loxP-neo region of the 21DqHAC vector. Genomic DNA was amplified using the following cycle conditions: 5 min at 94°C and then 35 cycles of (15 s at 94°C; 30 s at 64°C; 30 s at 72°C).
Animals and transplantation
All transplantation experiments were performed following guidelines of the animal ethical committee of Kirin Brewery Co. Ltd. Five-week-old NOD.CB17-Pakdc scid/J mice (The Jackson Laboratory, Bar Harbor, ME, USA) were subjected to 200 cGy of X-rays. Cultured hCB CD34+ cells were then injected into the tail vein.
Flow cytometry analysis and cell sorting For the colony-forming cells, the cells picked from methylcellulose culture were subjected to flow cytometry analysis (BECTON) to detect EGFP expression. The cells taken from the bone marrow of recipient mice two weeks post-transplantation were stained with phycoerythrin-conjugated anti-human CD45 (Pharmingen, San Diego, CA, USA) and allophycocyanin-conjugated anti-mouse CD45 (Pharmingen) and then analyzed by flow cytometry.
CD34
+ cell selection
The hCB CD34 + cells were prepared by MidiMACS (Miltenyi, Auburn, CA, USA). CB CD34 + cells were labeled with hapten-conjugated monoclonal antibodies against human CD34, followed by anti-hapten antibodies coupled to microbeads. The bead-positive cells (CD34 + cells) were enriched on magnetic columns.
Results and discussion
We previously developed the 21DqHAC vector that contains a minimized function of chromosomes of centromere and telomere obtained by truncation of chromosome 21. Here, we further explore the potential use of HAC vectors for gene therapy by introducing the 21DqHAC vector to human bone marrow or cord bloodderived hematopoietic cells. We transferred the 21DqHAC vector containing an EGFP transgene and a geneticin resistance marker (EGFP-21DqHAC) from CHO cells to hBM MNCs by MMCT. Subsequently, the cells were cultured for five days and then subjected to a clonogenic assay in the presence of geneticin. The mean number of geneticin-resistant colonies was 53±15.5 (standard deviation). Among them, the mean number of EGFP-positive colonies was 50±16.3 (standard deviation). The average transfer efficiency was 4.0·10 À4 , corresponding to a total of 53 geneticin-resistant colonies (20 granulocyte-macrophage colonies and 33 erythroid colonies) per 2.6·10 5 colony-forming cells (Fig. 1a) . We confirmed that the cells expressing EGFP actually carried the EGFP-21DqHAC by PCR. We observed expected size of PCR product for loxP-neo, suggesting that the 21DqHAC vector is maintained in these cells (Fig. 1b) . FACS analyses revealed that 72% of the cells in those colonies expressed EGFP (Fig. 1c) . The presence of the cells that do not express EGFP might be explained by the gradual loss of HAC vectors through continuous cell division or chromosome inactivation (Katoh et al 2004) . A fluorescence in situ hybridization analysis to detect the 21DqHAC vector was not successful due to technical difficulties with obtaining metaphase spreads of chromosome. Although we failed to demonstrate the independent existence of HAC in this study, other studies have shown that the 21DqHAC vector is maintained as an independent chromosome and is mitotically stable in human cell lines, primary human fibroblasts and human mesenchymal stem cells (Kakeda et al. 2005; Katoh et al.2004; Ren et al. 2005) . This observation supports the idea that the 21DqHAC vector is mitotically stable in human cells. May-Giemsa staining revealed that EGFP-expressing colonies contained not only erythroid cells but also various types of differentiated blood cells such as macrophages and primitive erythrocyte, in agreement with the results of the clonogenic assay (Fig. 1d) . These results proved that satisfactory transfer efficiencies and remarkably high percentages of transgene expression are obtained, and that the proper ability to successful differentiate into a variety of cell lineages is retained.
Next, we evaluated the in vivo repopulating potential of hematopoietic cells carrying the HAC by xenogenic transplantation. We introduced the EGFP-21DqHAC vector into purified cord blood-derived CD34-positive + ) via MMCT. These cells were cultured for five days in the presence of hSCF, hTPO, and FP6, and intravenously injected into sublethally irradiated NOD-SCID mice. Two weeks after transplantation, we harvested bone marrow cells and counted the cells that were positive for EGFP and hCD45 (human blood cell marker). Out of 1.2·10 4 hCD45-positive cells, 18 were found to be positive for EGFP. A PCR-based analysis revealed that HAC-derived PCR product was detected for EGFP + , hCD45 + cells, but not for EGFP -, hCD45 + cells (Fig. 1e ). These results demonstrate that cells carrying a HAC could still be observed in immunodeficient mice at two weeks post-transplantation.
Finally, we examined the possibility of expanding hematopoietic cells by introducing a gene conferring a growth advantage via our HAC system. We used ScFvg, a gp130-based chimeric receptor that transduces a growth signal in response to a ligand, fluorescein-conjugated BSA (BSA-Fl). The ScFvg-21DqHAC was introduced into hBM MNCs via MMCT and the cells were cultured for five days in the presence or absence of BSA-Fl prior to the clonogenic assay. There were 11.4±6.2 geneticin-resistant colonies in the untreated set and 50.4±33.1 geneticin-resistant colonies in the set treated with BSA-Fl ( Table 1 ). The number of colonies was not altered by the addition of BSA-Fl in normal hBM MNCs (data not shown). The total number of geneticin-resistant colonies increased by a factor of 4.3±1.0 with BSA-Fl. These data demonstrate that the ScFvg gene carried by the 21DqHAC vector was functional in hBM MNCs, and that it conferred a growth advantage to cells upon treatment with BSA-Fl.
We recently reported on the transfer of a HAC to primary human fibroblasts (Kakeda et al. 2005 ). To our knowledge, this is the second report of a successful transfer of a HAC into primary human cells and the first report of a successful transfer of a HAC into primary human hematopoietic cells, transplantation, and retention of these cells in bone marrow. Taken together, our results show the promise of HACs as tools for gene therapy. Our HAC-based system also provides a model for therapeutic gene delivery that is compatible with current clinical procedures such as bone marrow transplantation. Further improvements to HAC vector design and gene delivery systems to meet stringent clinical requirements will involve further study. 
